[Skip to Navigation]
October 1993

Intravenous Pentazocine and Methylphenidate Abuse During Pregna: Maternal Lifestyle and Infant Outcome

Author Affiliations

From the Newborn Follow-Up Program, Health Sciences Centre, Winnipeg, Manitoba (Dr Casiro and Ms Debooy), and the Department of Pediatrics, University of Manitoba, Winnipeg (Drs Seshia, Tenenbein and Casiro).

Am J Dis Child. 1993;147(10):1062-1065. doi:10.1001/archpedi.1993.02160340048012

• Objective.  —To report the effects of intravenous abuse of pentazocine hydrochloride and methylphenidate hydrochloride during pregnancy.

Design.  —Retrospective chart review.

Patients.  —All pregnant women and their offspring, whose hospital records indicated prenatal abuse of pentazocine and methylphenidate during the 2-year study period.

Results.  —The median for maternal age was 22 years and the median number of prenatal visits was two. Twenty mothers had sexually transmitted diseases, 27 abused alcohol, 10 abused other drugs, and all smoked cigarettes. Eight infants were premature, and 12 were growth retarded. Four infants had congenital anomalies: fetal alcohol syndrome (two [twins]), structural heart defect (one), and polydactyly (one). Eleven infants were treated for neonatal abstinence syndrome. Seventeen infants had normal developmental quotients, and four had low-normal developmental quotients.

Conclusions.  —Intrauterine exposure to pentazocine and methylphenidate appears to be associated with prematurity, growth retardation, and signs of neonatal withdrawal, but not with any particular teratogenic anomaly or severe developmental delay.(AJDC. 1993;147:1062-1065)

Add or change institution